DE60132531D1 - Pyridotriazine und Pyridopyridazine - Google Patents

Pyridotriazine und Pyridopyridazine

Info

Publication number
DE60132531D1
DE60132531D1 DE60132531T DE60132531T DE60132531D1 DE 60132531 D1 DE60132531 D1 DE 60132531D1 DE 60132531 T DE60132531 T DE 60132531T DE 60132531 T DE60132531 T DE 60132531T DE 60132531 D1 DE60132531 D1 DE 60132531D1
Authority
DE
Germany
Prior art keywords
pyridotriazines
pyridopyridazines
restenosis
angiogenesis
atherosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60132531T
Other languages
English (en)
Other versions
DE60132531T2 (de
Inventor
James Bernard Kramer
Howard Daniel Showalter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE60132531D1 publication Critical patent/DE60132531D1/de
Application granted granted Critical
Publication of DE60132531T2 publication Critical patent/DE60132531T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE60132531T 2000-10-03 2001-09-22 Pyridotriazine und Pyridopyridazine Expired - Fee Related DE60132531T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23760100P 2000-10-03 2000-10-03
US237601P 2000-10-03

Publications (2)

Publication Number Publication Date
DE60132531D1 true DE60132531D1 (de) 2008-03-13
DE60132531T2 DE60132531T2 (de) 2009-01-29

Family

ID=22894409

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60132531T Expired - Fee Related DE60132531T2 (de) 2000-10-03 2001-09-22 Pyridotriazine und Pyridopyridazine

Country Status (9)

Country Link
US (1) US6683183B2 (de)
EP (1) EP1195378B1 (de)
JP (1) JP3541829B2 (de)
AT (1) ATE384721T1 (de)
BR (1) BR0104395A (de)
CA (1) CA2356544C (de)
DE (1) DE60132531T2 (de)
ES (1) ES2296695T3 (de)
MX (1) MXPA01009551A (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002303145A1 (en) * 2001-03-23 2002-10-08 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
NZ566180A (en) 2005-07-29 2011-04-29 Resverlogix Corp Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
RU2520098C2 (ru) 2008-06-26 2014-06-20 Ресверлоджикс Корп. Способы получения производных хиназолинона
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
KR20180096823A (ko) 2009-04-22 2018-08-29 리스버로직스 코퍼레이션 신규한 소염제
RS58911B1 (sr) 2011-11-01 2019-08-30 Resverlogix Corp Oralne formulacije sa trenutnim otpuštanjem za supstituisane hinazolinone
SI3495358T1 (sl) 2012-11-08 2022-06-30 Bristol-Myers Squibb Company z amidi substituirane heterociklične spojine, uporabne kot modulatorji IL-12, IL-23 in/ali IFN alfa odzivov
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US11029951B2 (en) 2016-08-15 2021-06-08 Micron Technology, Inc. Smallest or largest value element determination

Also Published As

Publication number Publication date
US20020061865A1 (en) 2002-05-23
JP3541829B2 (ja) 2004-07-14
ATE384721T1 (de) 2008-02-15
CA2356544A1 (en) 2002-04-03
CA2356544C (en) 2006-04-04
ES2296695T3 (es) 2008-05-01
BR0104395A (pt) 2002-07-09
US6683183B2 (en) 2004-01-27
MXPA01009551A (es) 2002-04-12
JP2002121193A (ja) 2002-04-23
DE60132531T2 (de) 2009-01-29
EP1195378B1 (de) 2008-01-23
EP1195378A1 (de) 2002-04-10

Similar Documents

Publication Publication Date Title
DE60132531D1 (de) Pyridotriazine und Pyridopyridazine
TW200736231A (en) Substituted pyrimidines
NO972198D0 (no) 6-Aryl-pyrido£2,3-d|pyrimidiner og -naftyridiner for inhibering av protein-tyrosin-kinase-bevirket rask cellevekst
AU6475001A (en) Methods and apparatus for manufacturing an intravascular stent
ATE237617T1 (de) Bicyclische pyrimidine derivate und ihre verwendung als antikoagulantien
HK1149930A1 (en) Pyrimidineamines as angiogenesis modulators
ATE402177T1 (de) Bicyclische pyrimidine und bicyclische 3,4- dihydropyrimidine als inhibitoren der zellvermehrung
DE60206512D1 (de) Rapanycin29-enole
DK1814878T3 (da) Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf
DE59712873D1 (de) Halogenpyrimidinylaryl(thio)ether als pestizide
EP1156820A4 (de) Vaskulärer endothelialer wachstumsfaktor 2
DE69729877D1 (de) Mycophenol bisphosponatverbindungen
PL339745A1 (en) Agonists of apolipoprotein a-1 and their application in treating dislipidemic disorders
MXPA04001523A (es) Dialdehidos de rapamicina.
NO20005153L (no) Mutantprotein som har lavere allergenisk respons i mennesker og fremgangsmåter for konstruksjon, identifisering og fremstilling av slike proteiner
DK1557462T3 (da) Transplantataccept-inducerende celler af monocytisk oprindelse, deres fremstilling og anvendelse
DE602005015110D1 (de) 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer
TR199701669A1 (xx) Deri preparasyonu i�in bile�imler.
IL196900A0 (en) Autologous t-cell vaccines compositions
DE60235836D1 (de) Ahren und verwendung davon
WO2003010201A3 (en) Blood group antigen fusion polypeptides and methods of use thereof
WO2003000183A3 (en) Method of treating atherosclerosis and other inflammatory diseases
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
DK1127943T3 (da) Midler og fremgangsmåder til ekspression af homologe og heterologe proteiner i stammer af Rhodococcus
MXPA01002546A (es) Promocion o inibhicion de angiogenesis y cardiovascularizacion.

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: KRAMER, JAMES BERNARD, ANN ARBOR, MICH., US

Inventor name: SHOWALTER, HOWARD DANIEL, ANN ARBOR, MICH., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee